MTOR and lymphoma: The need for alternatives to mTOR inhibitors in lymphoma is further supported by a recent paper indicating that not all lymphoma-derived cell lines express 4E-BP1 and that lymphoma cells lacking 4E-BP1 are resistant to mTOR inhibitors [7].